24/7 MN – (NASDAQ: ACRX) stock is moving up this morning on news from Seeking Alpha about the company’s plan B.

The stock is up 23% in early trading on more than 5400 trades and 3.4 million in volume. Shares are trading around .31

AcelRx Pharmaceuticals: Finally, Plan B


  • On May 16, 2022 ACRX announced the company was in active discussions with potential commercial partners to take on DSUVIA.
  • In such case, ACRX would essentially give up the main asset on which its story was built on so far.
  • The company has acquired further assets over the past twelve months, ensuring a basis for further revenue.
  • Without knowledge of the DSUVIA deal it is hard to assess the prospect, so I retain a Neutral rating with a tilt to Buy, as I believe in some short-term upside potential.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist